News

Genetic engineering to prevent rejection in xenotransplantation

The major limitation involving the transplantation of cells, tissues and organs of animal origin (xenotransplantation, mostly of the pig) in humans is rejection due to the activation of various immune system mechanisms. Overcoming this limitation requires great efforts in xenotransplantation research, such as that led IDIBELL researcher Cristina Costa, who has devoted most of his […]

Leer más about Genetic engineering to prevent rejection in xenotransplantation

Manel Esteller, a world leader in cancer epigenetics and researcher at IDIBELL, receives National Research Prize 2015

The Government of Catalonia and the Catalan Foundation for Research and Innovation (FCRI) have awarded Manel Esteller, researcher at IDIBELL, the National Research Award 2015. Esteller is an ICREA research professor, director of the Epigenetics and Cancer Biology Program of the Institute of Biomedical Research of Bellvitge since 2008, head of the cancer Epigenetics Group of the center and professor of Genetics at the Department of Physiological Sciences II of the Faculty of Medicine of the University of Barcelona.

Leer más about Manel Esteller, a world leader in cancer epigenetics and researcher at IDIBELL, receives National Research Prize 2015

ERDF Funds subsidize new scientific equipment for IDIBELL

The Spanish Ministry of Economy and Competitiveness (MINECO) has granted a project to Bellvitge Biomedical Research Institute (IDIBELL) for the purchase of scientific equipment intended for laboratories, platforms and other scientific services with high-level technological instrumentation. The project, which is funded by the European Regional Development Fund (ERDF), has a total cost of € 2.290.725,9 […]

Leer más about ERDF Funds subsidize new scientific equipment for IDIBELL

UPC students, in collaboration with HUB and IDIBELL present new technologies to improve the treatment of facial paralysis

“Software of image processing as facial neuromuscular therapy in patients with peripheral facial paralysis” is the second project born of the agreement between the Polytechnic University of Catalonia, the University Hospital of Bellvitge (HUB) and IDIBELL to promote biomedical research and technology transfer. On the one hand, the agreement enables UPC students learn about the […]

Leer más about UPC students, in collaboration with HUB and IDIBELL present new technologies to improve the treatment of facial paralysis

10% of sporadic colon tumors have mutations in the gene AMER1

Sanz-Pamplona R, Lopez-Doriga A, Paré-Brunet L, Lázaro K, Bellido F, Alonso MH, Aussó S, Guinó E, Beltrán S, Castro-Giner F, Gut M, Sanjuan X, Closa A, Cordero D, Morón-Duran FD, Soriano A, Salazar R, Valle L, Moreno V. Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer. Clinical Cancer Research 2015; 21(20):4709-18. doi: 10.1158/1078-0432.CCR-15-0159

Leer más about 10% of sporadic colon tumors have mutations in the gene AMER1

IDIBELL is positioned in favor of Open Access policies

The Bellvitge Biomedical Research Institute (IDIBELL) has signed the statement of the League of European Research Universities (LERU) to promote Open Access policies in the dissemination of scientific results. According to the manifesto, European universities allocate a significant portion of their budgets to scientific journals publishers. Hundreds of millions of euro’s. Money which is not […]

Leer más about IDIBELL is positioned in favor of Open Access policies

IDIBELL participates in Giving Tuesday with the project ”Let research flies’

Funds will go to the IDIBELL Biomedical Research Grants Program aimed at young researchers About GivingTuesday

Leer más about IDIBELL participates in Giving Tuesday with the project ”Let research flies’
Scroll to Top